Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Long-term Potentiation01:35

Long-term Potentiation

59.2K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
59.2K
Long-term Potentiation01:25

Long-term Potentiation

3.8K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
3.8K
The Blood-brain Barrier00:49

The Blood-brain Barrier

54.7K
Overview
54.7K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria.

Nature medicine·2026
Same author

Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Cerebellar magnetization transfer ratio and its relationship to clinical outcomes in radiologically isolated syndrome and multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Increased PET <sup>11</sup>C-PBR28 binding in multiple sclerosis normal-appearing white matter correlates with MRI measures of myelin loss.

Multiple sclerosis and related disorders·2026
Same author

Monitoring morphometric drift in lifelong learning segmentation of the spinal cord.

Imaging neuroscience (Cambridge, Mass.)·2026

Related Experiment Video

Updated: Mar 15, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K

Brain health: time matters in multiple sclerosis.

Gavin Giovannoni1, Helmut Butzkueven2, Suhayl Dhib-Jalbut3

  • 1Queen Mary University London, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK.

Multiple Sclerosis and Related Disorders
|September 20, 2016
PubMed
Summary

International recommendations aim to improve multiple sclerosis (MS) care by emphasizing early diagnosis, proactive monitoring, and shared decision-making. Improving access to disease-modifying therapies (DMTs) is crucial for better outcomes in MS patients.

Keywords:
Consensus statementDisease activityDisease-modifying therapy (DMT)Magnetic resonance imaging (MRI)Multiple sclerosisTreatment strategy

More Related Videos

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

10.0K

Related Experiment Videos

Last Updated: Mar 15, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

10.0K

Area of Science:

  • Neurology
  • Immunology
  • Public Health

Background:

  • Multiple sclerosis (MS) presents significant personal and economic challenges.
  • Current practices in MS diagnosis, management, and treatment access require improvement.
  • Barriers to accessing disease-modifying therapies (DMTs) hinder optimal patient care.

Purpose of the Study:

  • To establish international consensus recommendations for enhancing MS diagnosis.
  • To improve management strategies and treatment access for individuals with MS.
  • To foster a better future for people affected by MS and their families.

Main Methods:

  • Structured discussions and literature reviews were conducted in 2015.
  • Analysis focused on the impact of MS, current treatment paradigms, and access barriers.
  • Key areas examined included diagnosis, disease activity definitions, and DMT accessibility.

Main Results:

  • Delays in neurologist consultation for MS symptoms are common.
  • Early initiation of DMTs and lifestyle interventions are recommended.
  • Proactive monitoring, shared decision-making, and improved access to DMTs are essential for managing MS.

Conclusions:

  • International consensus supports a proactive therapeutic strategy for MS.
  • Shared decision-making and early diagnosis are critical components of optimal MS care.
  • Addressing treatment access barriers is vital for improving outcomes in multiple sclerosis.